Loading…
Loading…
MRVL.V does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MRVL.V and 80,000+ other tickers.
See exactly how MRVL.V's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MRVL.V and 80,000+ other tickers.
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company’s lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer’s disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.
Marvell Technology, Inc. (NASDAQ: MRVL - Get Free Report)'s stock price rose 2.1% during mid-day trading on Monday after B. Riley Financial raised their price target on the stock from $135.00 to $156.00. B. Riley Financial currently has a buy rating on the stock. Marvell Technology traded as high as $133.20 and last traded at $131.1810.
Hager Investment Management Services LLC lessened its stake in Marvell Technology, Inc. (NASDAQ: MRVL) by 27.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,001 shares of the semiconductor company's stock after selling 6,859 shares during the quarter.
Marvell Technology, Inc. (NASDAQ: MRVL - Get Free Report) COO Chris Koopmans sold 10,000 shares of the company's stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $110.24, for a total transaction of $1,102,400.00. Following the sale, the chief operating officer owned 133,870 shares in the company, valued
Marvell Technology, Inc. (NASDAQ: MRVL - Get Free Report) EVP Mark Casper sold 6,900 shares of the business's stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $109.45, for a total value of $755,205.00. Following the completion of the sale, the executive vice president owned 10,263 shares in
Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), is pleased to announce that